The Enterprise Value as of December 2024 (TTM) for Relmada Therapeutics, Inc. (RLMD) is 9.42M

According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.42M. This represents a change of -91.68% compared to the average of 113.26M of the last 4 quarters.

Relmada Therapeutics, Inc. (RLMD) Historical Enterprise Value (quarterly & annually)

How has RLMD Enterprise Value performed in the past?

The mean historical Enterprise Value of Relmada Therapeutics, Inc. over the last ten years is 154.68M. The current 9.42M Enterprise Value has changed 509.08% with respect to the historical average. Over the past ten years (40 quarters), RLMD's Enterprise Value was at its highest in in the September 2022 quarter at 1.07B. The Enterprise Value was at its lowest in in the December 2017 quarter at 4.86M.

Relmada Therapeutics, Inc. (RLMD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Relmada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Relmada Therapeutics, Inc. (RLMD) Average Enterprise Value

How has RLMD Enterprise Value performed in the past?

The current Enterprise Value of Relmada Therapeutics, Inc. (RLMD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Relmada Therapeutics, Inc. (RLMD) Enterprise Value vs. Peers

How is RLMD’s Enterprise Value compared to its peers?

Relmada Therapeutics, Inc.’s Enterprise Value is less than Cytokinetics, Incorporated (6.47B), less than DICE Therapeutics, Inc. (1.82B), less than Edgewise Therapeutics, Inc. (2.76B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (1.93B), less than Third Harmonic Bio, Inc. (172.31M), less than PMV Pharmaceuticals, Inc. (40.53M), less than Enochian Biosciences, Inc. (167.08M), less than Revolution Medicines, Inc. (7.98B), less than Pardes Biosciences, Inc. (75.90M), less than Shattuck Labs, Inc. (12.78M), less than Eliem Therapeutics, Inc. (0), less than Champions Oncology, Inc. (112.78M), less than Century Therapeutics, Inc. (89.16M), less than Fusion Pharmaceuticals Inc. (1.87B), less than Bicycle Therapeutics plc (134.07M), less than RAPT Therapeutics, Inc. (27.70M), less than NewAmsterdam Pharma Company N.V. (2.35B), greater than Cyteir Therapeutics, Inc. (-20511738.00), less than Nuvation Bio Inc. (930.27M), greater than Magenta Therapeutics, Inc. (-114170976.00), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Graphite Bio, Inc. (-15007658.00),

Build a custom stock screener for Relmada Therapeutics, Inc. (RLMD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relmada Therapeutics, Inc. (RLMD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.